1. Abstract LBA3, Alan P. Venook et al.
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
http://abstracts.asco.org/144/AbstView_144_126013.html
Dr. Johanna Bendell
2. Abstract 3503, Dirk Arnold et al.
Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).
http://abstracts.asco.org/144/AbstView_144_133066.html
3. Abstract 3504, Miriam Koopman et al.
Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC).
http://abstracts.asco.org/144/AbstView_144_131325.html
4. Abstract 3506, Fortunato Ciardiello et al.
Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.
http://abstracts.asco.org/144/AbstView_144_127862.html
5. Abstract 4005, Shuichi Hironaha et al.
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy – Efficacy analysis in Japanese and Western patients.
http://abstracts.asco.org/144/AbstView_144_132412.html
6. Abstract 4000, Herbert Hurwitz et al.
RECAP: A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
http://abstracts.asco.org/144/AbstView_144_128761.html
Dr. Johanna C. Bendell is the director of GI cancer research and associate director of the drug development unit at the Sarah Cannon Research Institute, Nashville, Tenn.